Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

as compared to Q3 2010.

2.    Royalties

Year on year growth Royalties to Product Shire $M Royalties CER ADDERALL XR 1.00 22.9 27% 27% 3TC and ZEFFIX 1.00 17.3 -57% -58% FOSRENOL 1.00 10.9 56% 56% Other 1.00 11.7 7% 0% Total 1.00 62.8 -18% -19%

Royalty income decreased in Q3 2011 compared to Q3 2010 as higher royalties on ADDERALL XR and FOSRENOL were more than offset by lower royalties from 3TC and ZEFFIX.

Royalty income from 3TC and ZEFFIX continues to be adversely impacted by increased competition from other products. Additionally, in Q3 2011 Shire has continued to not recognize royalty income for 3TC for certain territories due to a disagreement between GSK and Shire about how the relevant royalty rate should be applied given the expiry dates of certain patents. In Q3 2011 this disagreement extended to ZEFFIX, and accordingly Shire has not recognized ZEFFIX royalty income for the affected territories. GSK and Shire continue to hold discussions in order to clarify this issue.

3.    Financial details

Cost of product sales

% of % of product product Q3 2011 sales Q3 2010 sales $M $M Cost of product sales (US GAAP) 166.5 16% 112.7 14% Unwind of DERMAGRAFT inventory fair value step-up on acquisition (9.0) - Transfer of manufacturing from Owings Mills (3.4) (7.3) Depreciation (8.6) (2.3) Cost of product sales (Non GAAP) 145.5 14% 103.1 13%

Non GAAP cost of product sales as a percentage of product sales increased in Q3 2011 compared to the same period in 2010 due to the inclusion of DERMAGRAFT and the impact of a $10.0 million inventory write down of expired ELAPRASE unpurified bulk material, which was not prioritised for purification as capacity was directed towards meeting demand for REPLAGAL and VPRIV.

US GAAP cost of product sales as a percentage of product sales was two percentage points higher than the same period in 2010 due to the ELAPRASE write dow
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Proove ... medicine, is excited to announce a new genetic test ... The Proove Pain Perception Test will provide physicians ... and why pain tolerance levels are stratified between individuals. ... identify whether a person has a genetic predisposition that ...
(Date:9/30/2014)... September 30, 2014 Fast, ... of chemistry in documents ChemAxon ... and consulting services for life science research, launches ... generate Markush structures from documents. Markush ... property, however generating and understanding Markush structures is ...
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
(Date:9/30/2014)... 2014 The custom stainless steel fabrication ... Show 2014. The Boston Area Chapter of ISPE (International ... day-long event for Wed., Oct. 1 at Gillette Stadium ... the largest in ISPE Boston’s long history, with more ... attendees expected. , HOLLOWAY AMERICA President David Simpson ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3
... Dec. 9 The results of a new study on ... 30 sites around the country, will be published in the ... Salloway, MD, MS, director of the Butler Hospital Memory and ... the Warren Alpert Medical School of Brown University, says that ...
... , SAN DIEGO, Dec. 9 ... life-saving medicines specifically designed to enhance the perfusion and ... and other gas delivery, today announced that the European ... MP4CO for the treatment of sickle cell disease. This ...
... ... Platform for High Throughput and High Content Screening. , ... Basel, Switzerland and Granada, Spain (PRWEB) December 8, ... discovery and life science research, and Fundación MEDINA (Centro de Excelencia en ...
Cached Biology Technology:Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4
(Date:9/30/2014)... think of nature as something that we enjoy when we ... Or do we think of ourselves as a part of ... what about a house? , The answers to these ... our actions, our speech and in cultural artifacts. , A ... Washington, the American Indian Center of Chicago and the Menominee ...
(Date:9/30/2014)... WASHINGTON, D.C., September 30, 2014--Sea monkeys have captured the ... of their easily observable life cycle -- sold as ... and mate given little more than a tank of ... a shorter-term pattern: Like other zooplankton, brine shrimp vertically ... conditions, coming closer to the surface at night and ...
(Date:9/30/2014)... engineers, led by Clemson University associate professor Brian ... from the U.S. Department of Energy,s Experimental Program ... positive impact on South Carolina in the advancement ... , "Understanding the scientific and engineering needs for ... nuclear technologies is imperative if South Carolina is ...
Breaking Biology News(10 mins):The cultural side of science communication 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
... anywhere, a researcher at the Hebrew University of Jerusalem has ... the brain of a mammal. , Dr. Adi Mizrahi ... of Life Sciences at the Hebrew University, used mouse models ... undifferentiated cellular sphere into a rich and complex cell. This ...
... cure type 1 diabetes by allowing people to ... defective pancreas, medical researchers here have reported that they ... cord blood to produce insulin. , The researchers announced ... research, in the June 2007 issue of the medical ...
... organism that produces the world’s most lethal toxin is revealed today. ... Clostridium botulinum and less than 2 kg — the weight of ... on the planet. Very small amounts of the same toxin are ... , The genome sequence shows that C. botulinum doesn’t have subtle ...
Cached Biology News:A first -- Hebrew University scientist observes brain cell development in 'real time' 2Adult stem cells from human cord umbilical cord blood successfully engineered to make insulin 2Adult stem cells from human cord umbilical cord blood successfully engineered to make insulin 3Genome of Clostridium botulinum reveals the background to world's deadliest toxin 2Genome of Clostridium botulinum reveals the background to world's deadliest toxin 3
... Immunogen: synthetic peptide corresponding to the ... dopamine receptor, conjugated to KLH. The ... rat and mouse gene. Physical form: ... containing 0.01% sodium azide. Titertest method: ...
... The National Collection of Pathogenic ... authenticated human pathogenic viruses in ... is able to supply the ... from them, to the scientific ...
... The flexible and easy ... used to control all members ... family. It features a clear ... visual assay setup, user-friendly and ...
Roll of Mesh 5m x 25cm...
Biology Products: